06Oct 2021
Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

We evaluated gastrointestinal (GI) adverse events (AEs) with once‐weekly semaglutide 2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL). GI AEs were more common with semaglutide 2.4 mg than placebo, but typically mild‐to‐moderate and transient. Semaglutide‐induced WL was largely independent of GI AEs.

  • #endo-diabetology

Like

Save

Share